Dyne Therapeutics (NASDAQ:DYN) Announces Quarterly Earnings Results, Misses Estimates By $0.25 EPS

Dyne Therapeutics (NASDAQ:DYN) announced its earnings results on Tuesday. The company reported ($0.96) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.25), Zacks reports.

Dyne Therapeutics Price Performance

Dyne Therapeutics stock traded up $5.08 during mid-day trading on Wednesday, reaching $34.41. 1,287,033 shares of the company’s stock were exchanged, compared to its average volume of 1,490,784. Dyne Therapeutics has a twelve month low of $9.26 and a twelve month high of $47.45. The company has a fifty day moving average of $32.63 and a 200-day moving average of $35.12.

Insiders Place Their Bets

In other Dyne Therapeutics news, Director Dirk Kersten sold 23,671 shares of the stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $35.35, for a total transaction of $836,769.85. Following the sale, the director now directly owns 99,652 shares in the company, valued at $3,522,698.20. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, Director Dirk Kersten sold 23,671 shares of the firm’s stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $35.35, for a total value of $836,769.85. Following the sale, the director now directly owns 99,652 shares in the company, valued at approximately $3,522,698.20. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Susanna Gatti High sold 8,976 shares of Dyne Therapeutics stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $34.41, for a total transaction of $308,864.16. Following the sale, the chief operating officer now owns 131,636 shares in the company, valued at $4,529,594.76. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 158,975 shares of company stock worth $5,693,789 in the last ninety days. 20.77% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on DYN. Oppenheimer reissued an “outperform” rating and set a $55.00 target price on shares of Dyne Therapeutics in a research note on Tuesday, September 3rd. HC Wainwright restated a “buy” rating and set a $55.00 price target on shares of Dyne Therapeutics in a research report on Wednesday. Stifel Nicolaus increased their price target on shares of Dyne Therapeutics from $41.00 to $66.00 and gave the company a “buy” rating in a research note on Friday, August 16th. Morgan Stanley increased their price target on shares of Dyne Therapeutics from $48.00 to $52.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. Finally, StockNews.com cut shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 16th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $50.60.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.